Researchers at the University of Pennsylvania and Mayo Clinic have developed a blood test that detects pancreatic cancer with 91.9% accuracy by combining four protein biomarkers. The test identified 87.5% of early-stage (I/II) cases — a critical advance for a disease where only 1 in 10 patients survive beyond five years due to late diagnosis.
Lead researcher Dr. Kenneth Zaret's team studied 672 individuals and identified two new blood markers — aminopeptidase N (ANPEP) and polymeric immunoglobulin receptor (PIGR) — that, when combined with existing markers CA19-9 and THBS2, dramatically improved detection. The test maintained just a 5% false positive rate and successfully distinguished cancer patients from those with non-cancerous conditions like pancreatitis.
